Trial Profile
Phase I, Open-Label Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Ceralasertib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2022 Status changed from recruiting to completed.
- 11 May 2021 Results published in the Clinical Cancer Research
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology